

Patient and Provider Satisfaction With the Oxbryta® (Voxelotor) Hub Service Program: A Retrospective Analysis

Anne Beaubrun, PhD; Rupali Sardesai, MS; Nikhil Bhat, MBA; Rochon Kim, MBA; Irene Agodoa, MD
Global Blood Therapeutics, Inc, South San Francisco, CA, USA

BACKGROUND

- Sickle cell disease (SCD) is a chronic, debilitating disorder that requires consistent lifelong management to mitigate SCD-related complications and reduce the risk of early mortality.^{1,2}
- Disease-modifying therapies such as Oxbryta® (voxelotor) tablets that inhibit hemoglobin S polymerization and subsequent 'sickling' of red blood cells have the potential to reduce the risk of morbidity in patients with SCD.³
- Due to a variety of factors including access to care, comorbidities, reimbursement, and patient-provider communication, the initiation of and adherence to treatment by patients with SCD remain poor.^{1,2}
- To provide additional patient support, Global Blood Therapeutics (GBT) implemented a hub service program (HUB) for Oxbryta, GBT Source Solutions®, to offer patient education and support, assist with reimbursement services, and connect patients to GBT's specialty pharmacy (SP) network.⁴
- Identifying effective interventions to support patient initiation of and adherence to treatment is crucial for improving care and decreasing health disparities for patients with SCD.²

OBJECTIVES

- To assess patient, healthcare provider (HCP), and practice manager satisfaction with the Oxbryta HUB in Q1 2021.
- To describe the impact of HUB enrollment on initiation of and adherence to treatment in patients with SCD who were prescribed Oxbryta from December 2019 to December 2020.


METHODS

- Real-world patient data were compiled from the HUB, GBT Source Solutions®.
 - HUB services included connecting patients with care coordinators to better understand their insurance benefits, a nurse support team to answer their questions about their medication, and provider-to-provider services, including medication dispensing and therapy monitoring.
- Patients with SCD aged ≥12 years who were prescribed Oxbryta from December 2019 to December 2020 were included in this retrospective analysis.
- To assess patient satisfaction with the HUB, a 35-minute online survey from Q1 2021 was used to understand patients' beliefs around SCD treatment as well as their perceptions of the HUB.
- To assess HCP and practice manager satisfaction with the HUB, a 30-minute online survey was sent directly to participants during Q1 2021.
 - Data were weighted by respondents' self-reported SCD patient load.
- The percentage of patients who initiated Oxbryta after being enrolled in the HUB and patient adherence to treatment were assessed.
 - Adherence was calculated using the medication-possession ratio, defined as the percentage of available prescriptions filled at 180 days following treatment initiation.

RESULTS

- In total, approximately 5000 patients were included in the analysis.
- Among those who consented, 60% were women, with the majority of patients between the ages of 12 and 34 years.
- Approximately 40% of HUB patients received Medicaid (Figure 1).
 - The majority of patients received either Medicare Part D/dual coverage (approximately 30%) or commercial insurance (approximately 30%).


Figure 1. Payer Mix Among Patients Enrolled in HUB Services



FFS, fee for service; HUB, hub service program; PAP, patient assistance program.

- Among HUB patient respondents, overall satisfaction with the HUB was high across all services, with mean satisfaction scores ≥5.3 out of a possible 6 points (Figure 2).


Figure 2. Patient Satisfaction With HUB Services



HUB, hub service program; SCD, sickle cell disease.

- Among HCPs who responded to the satisfaction survey, there were similar proportions of hematology/oncology physicians, primary care physicians, and pediatricians (approximately 30% each).
 - Among HCPs, overall satisfaction with the HUB and patient support services was high, with a mean satisfaction score of 5.6 out of 7 possible points (Figure 3).


Figure 3. HCP Satisfaction With HUB Services



HCP, healthcare provider; HUB, hub service program.

- Similarly, overall satisfaction among practice managers who referred patients to the HUB was high, with a mean satisfaction score of 5.0 out of 6 possible points (Figure 4).
 - Satisfaction with HUB services was also consistent across specialty practices, including primary care (mean 4.9), pediatrics (mean 4.9), hematology/oncology (mean 5.2), and pediatric hematology/oncology (mean 5.1).

Figure 4. Practice Manager Satisfaction With HUB Services



HUB, hub service program.

- After enrollment in the HUB, a high percentage of patients (76%) initiated Oxbryta treatment.
- Over the first 180 days of therapy, HUB patients had high rates of adherence.

CONCLUSIONS

- In this real-world, retrospective analysis, enrollment in the Oxbryta HUB (GBT Source Solutions®), a comprehensive program that provides patient access to support and education, resulted in high rates of patient initiation of and adherence to Oxbryta treatment.
- Overall, patients' satisfaction with the HUB was high across services used, including financial assistance for eligible patients, help getting medication, prior authorization processing, and refill reminders.
- Similarly, satisfaction with HUB services was high among HCPs and practice managers across specialties who referred patients to GBT Source Solutions®.
- Physician reinforcement of the potential advantages of a HUB service at the time of prescribing may be a beneficial intervention to advance meaningful treatment outcomes for patients with SCD.

References

- Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. *Nat Rev Dis Primers*. 2018;4:18010.
- Loiselle K, Lee JL, Szulczewski L, et al. Systematic and meta-analytic review: medication adherence among pediatric patients with sickle cell disease. *J Pediatr Psychol*. 2016;41(4):406-418.
- Nardo-Marino A, Brousee V, Rees D. Emerging therapies in sickle cell disease. *Br J Haematol*. 2020;190(2):149-172.
- GBT Source Solutions®. Patient Brochure. Global Blood Therapeutics. Accessed May 4, 2021. <https://oxbryta.com/pdf/gbt-source-solutions-brochure.pdf>

Acknowledgments

- We thank all the patients with sickle cell disease, families, and caregivers who contributed to this study.

Disclosures

- All authors:** Global Blood Therapeutics, Inc. employees and equity ownership.
- Renee Symonds, PhD (Healthcare Consultancy Group, with funding from Global Blood Therapeutics) provided editorial assistance in the preparation of this report.
- This study was supported by Global Blood Therapeutics.